Lymphoblastic Lymphoma

• EMA approval · 2025-09-17
  EMA Authorised: Besponsa (Inotuzumab ozogamicin) — Pfizer Europe MA EEIG

  The European Medicines Agency authorised Besponsa (inotuzumab ozogamicin) for precursor cell lymphoblastic leukemia-lymphoma under Pfizer Eu…

• FDA approval · 2023-06-15
  FDA Approved: CYTARABINE — Supplemental Application (Meitheal Pharmaceuticals Inc.)

  FDA approved a supplemental application for Cytarabine from Meitheal Pharmaceuticals Inc., completing a modification to the existing Cytarab…

• FDA approval · 2021-01-14
  FDA Approved: VINCRISTINE SULFATE — Supplemental Application (Hospira, Inc.)

  The FDA approved a supplemental application filed by Hospira for vincristine sulfate, a generic vincristine product.